IJTLD open · 2025
Development and evaluation of the phenotypic 2G test to detect drug-resistant TB.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Garcia J I, Mambuque E T, Hicks A D, Schami A, Munguambe S, Gomez N, Tembe G, Saavedra B, Wang S-H, Balada-Llasat J-M, Restrepo B I, Yotebieng M, Gelfond J, Garcia-Basteiro A L, Torrelles J B
Аннотация
BACKGROUND: Early diagnosis of TB with drug susceptibility testing (DST) is critical to achieve successful treatment outcomes. We aimed to develop and test a novel colorimetric, 12-well, thin-layer agar-based test to assess its accuracy for TB diagnosis and DST in a clinical setting in Southern Mozambique.
METHODS: Development of the first prototype of the second generation (2G) test in the laboratory setting followed by a cross-sectional diagnostic accuracy study with consecutive recruitment of subjects with microbiologically confirmed TB using GeneXpert MTB/RIF Ultra.
RESULTS: In the laboratory setting, the 2G test showed 100% accuracy in detecting resistance of genotypically characterised drug-resistant Mycobacterium tuberculosis strains. In the clinical setting, the sensitivity of the 2G test to detect M.tb complex versus Xpert and Mycobacteria Growth Indicator Tube (MGIT) culture using fresh sputa was 45.9% and 45.2%, respectively. The 2G test sensitivity versus MGIT decreased to 23.1% when using frozen decontaminated sputum samples.
CONCLUSION: In the clinical setting, the 2G test showed a low sensitivity versus Xpert and MGIT. The 2G test sensitivity was lower when frozen instead of fresh sputa was used. Despite these results, important information was collected to further improve this 2G test prototype and its implementation in resource-constrained settings.
METHODS: Development of the first prototype of the second generation (2G) test in the laboratory setting followed by a cross-sectional diagnostic accuracy study with consecutive recruitment of subjects with microbiologically confirmed TB using GeneXpert MTB/RIF Ultra.
RESULTS: In the laboratory setting, the 2G test showed 100% accuracy in detecting resistance of genotypically characterised drug-resistant Mycobacterium tuberculosis strains. In the clinical setting, the sensitivity of the 2G test to detect M.tb complex versus Xpert and Mycobacteria Growth Indicator Tube (MGIT) culture using fresh sputa was 45.9% and 45.2%, respectively. The 2G test sensitivity versus MGIT decreased to 23.1% when using frozen decontaminated sputum samples.
CONCLUSION: In the clinical setting, the 2G test showed a low sensitivity versus Xpert and MGIT. The 2G test sensitivity was lower when frozen instead of fresh sputa was used. Despite these results, important information was collected to further improve this 2G test prototype and its implementation in resource-constrained settings.